SCARTOZZI, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.129
AS - Asia 1.266
EU - Europa 1.051
SA - Sud America 216
AF - Africa 22
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.692
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.095
SG - Singapore 497
GB - Regno Unito 349
CN - Cina 255
HK - Hong Kong 203
BR - Brasile 179
DE - Germania 161
SE - Svezia 138
VN - Vietnam 119
IT - Italia 104
RU - Federazione Russa 72
FI - Finlandia 67
TR - Turchia 62
FR - Francia 46
ID - Indonesia 36
BG - Bulgaria 31
IN - India 22
JP - Giappone 21
AR - Argentina 17
NL - Olanda 14
UA - Ucraina 14
CA - Canada 12
IE - Irlanda 11
IQ - Iraq 9
AT - Austria 8
MX - Messico 7
BD - Bangladesh 6
VE - Venezuela 6
BE - Belgio 5
EC - Ecuador 5
BZ - Belize 4
JM - Giamaica 4
LU - Lussemburgo 4
MA - Marocco 4
NO - Norvegia 4
RO - Romania 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
AU - Australia 3
CZ - Repubblica Ceca 3
IL - Israele 3
KR - Corea 3
MY - Malesia 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EG - Egitto 2
ES - Italia 2
GT - Guatemala 2
JO - Giordania 2
KE - Kenya 2
LT - Lituania 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
PE - Perù 2
PH - Filippine 2
PL - Polonia 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BW - Botswana 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EE - Estonia 1
IR - Iran 1
KZ - Kazakistan 1
LV - Lettonia 1
MC - Monaco 1
MD - Moldavia 1
ML - Mali 1
MZ - Mozambico 1
PA - Panama 1
PG - Papua Nuova Guinea 1
PK - Pakistan 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
TW - Taiwan 1
UG - Uganda 1
Totale 6.692
Salva come PNG Salva come JPEG
Città #
Fairfield 712
Ashburn 437
Santa Clara 392
Singapore 335
Seattle 302
Woodbridge 292
Chandler 251
Houston 248
Cambridge 218
Wilmington 218
Southend 210
Hong Kong 202
Dearborn 117
Nyköping 106
London 97
Ann Arbor 74
Izmir 58
New York 58
Helsinki 56
Beijing 45
Dong Ket 44
San Diego 43
Jakarta 34
Munich 32
Princeton 31
Sofia 31
Bremen 30
Eugene 30
Phoenix 28
Ho Chi Minh City 25
Shanghai 24
Los Angeles 19
São Paulo 19
Tokyo 19
Chicago 18
Modena 18
Hanoi 17
Lauterbourg 16
Redondo Beach 15
Council Bluffs 14
Milan 13
Boardman 12
Dublin 11
Falkenstein 10
Buffalo 9
Dallas 9
Jacksonville 9
Turku 9
Frankfurt am Main 8
Hefei 8
Portsmouth 8
The Dalles 8
Atlanta 7
Kunming 7
Moscow 7
Norwalk 7
Curitiba 6
Hanover 6
San Jose 6
Chennai 5
Guangzhou 5
Jieyang 5
Orem 5
Rio de Janeiro 5
Salt Lake City 5
Toronto 5
Amsterdam 4
Baghdad 4
Belize City 4
Brooklyn 4
Brussels 4
Criciúma 4
Denver 4
Düsseldorf 4
Edinburgh 4
Hounslow 4
Jinan 4
Montreal 4
Mumbai 4
Nanjing 4
Redwood City 4
San Francisco 4
San Mateo 4
Vienna 4
Zhengzhou 4
Bari 3
Belo Horizonte 3
Cascina 3
Charlotte 3
City of London 3
Columbus 3
Florence 3
Gunzenhausen 3
Haiphong 3
Hangzhou 3
Harbin 3
Hyderabad 3
Nuremberg 3
Oslo 3
Quito 3
Totale 5.251
Salva come PNG Salva come JPEG
Nome #
Immunotherapy for colorectal cancer: where are we heading? 288
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 284
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 258
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients 257
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma 252
Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma 243
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 238
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 234
Efficacy of sorafenib in BRAF-mutated nonsmall- cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report 231
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol 228
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale 226
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) 225
Immunotherapeutic approaches for hepatocellular carcinoma 225
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib 224
Multimodal treatment of resectable pancreatic ductal adenocarcinoma 223
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 222
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study 219
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 217
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib 214
Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study 213
The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer 211
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma 206
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC) 205
The Italian Rare Pancreatic Exocrine Cancer Initiative 205
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study 204
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 194
Systemic chemotherapy for advanced rare pancreatic histotype tumors: A retrospective multicenter analysis 186
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 181
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 159
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? 155
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 81
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 80
Totale 6.788
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.212
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.212
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021653 0 0 0 0 0 112 80 90 70 112 86 103
2021/2022628 80 22 23 36 15 45 13 49 62 76 129 78
2022/2023727 87 80 40 59 105 80 16 75 86 9 46 44
2023/2024288 9 16 10 45 65 2 33 40 3 7 8 50
2024/20251.399 39 24 5 116 286 229 141 84 190 45 75 165
2025/2026848 125 47 97 179 366 34 0 0 0 0 0 0
Totale 6.788